Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 24, 2020 - Issue 3
Submit an article Journal homepage
322
Views
3
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Targeting genetically-tuned CAFs in pancreatic cancer via perlecan manipulation

Shona RitchieCancer Theme, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia;St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, AustraliaView further author information
,
Brooke A. PereiraCancer Theme, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia;St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, AustraliaView further author information
,
Claire VenninMolecular Pathology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsCorrespondence[email protected]
View further author information
&
Paul TimpsonCancer Theme, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia;St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5514-7080View further author information
ORCID Icon
Pages 171-174 | Received 09 Oct 2019, Accepted 06 Feb 2020, Published online: 13 Feb 2020

References

  • Vennin C, Mélénec P, Rouet R, et al. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nat Commun. 2019;10(1):3637.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
  • Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.
  • Pereira B, Vennin C, Papanicolaou M, et al. CAF subpopulations: a new reservoir of stromal targets in pancreatic cancer. Trends Cancer. 2019;5:724–741.
  • Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: randomized phase ii study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2018;36(4):359–366.
  • Follain G, Herrmann D, Harlepp S, et al. Fluids and their mechanics in tumour transit: shaping metastasis. Nat Rev Cancer. 2020;20:107–124.
  • Vennin C, Murphy KJ, Morton JP, et al. Reshaping the tumor stroma for treatment of pancreatic cancer. Gastroenterology. 2018;154:820–838.
  • Neesse A, Bauer CA, Öhlund D, et al. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut. 2019;68(1):159–171.
  • De Jaeghere EA, Denys EH, De Wever O. Fibroblasts fuel immune escape in the tumor microenvironment. Trends Cancer. 2019;5:704–723.
  • Ohlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–596.
  • Biffi G, Oni TE, Spielman B, et al. IL1-induced JAK/STAT signaling is antagonized by tgfβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9(2):282–301.
  • Elyada E, Bolisetty M, Laise P, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9:1102–1123. CD-19-0094.
  • Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304–317.
  • Grindel B, Li Q, Arnold R, et al. Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients. Oncotarget. 2016;7(9):10433–10447.
  • Warren C, Grindel BJ, Francis L, et al. Transcriptional activation by NFkappaB increases perlecan/HSPG2 expression in the desmoplastic prostate tumor microenvironment. J Cell Biochem. 2014;115:1322–1333.
  • Vennin C, Chin VT, Warren SC, et al. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Sci Transl Med. 2017;9(384):eaai8504.
  • Tian C, Clauser KR, Öhlund D, et al. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc Natl Acad Sci U S A. 2019;116(39):19609–19618.
  • Kalscheuer S, Khanna V, Kim H, et al. Discovery of HSPG2 (Perlecan) as a therapeutic target in triple negative breast cancer. Sci Rep. 2019;9:12492.
  • Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer. 2012;12(2):121–132.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.